Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Claudin18.2 CAR-T (CT041) in Patients With Gastric or Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04404595
Recruitment Status : Recruiting
First Posted : May 27, 2020
Last Update Posted : February 24, 2022
Information provided by (Responsible Party):
CARsgen Therapeutics Co., Ltd.

Brief Summary:
A Phase 1b, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric or pancreatic adenocarcinoma

Condition or disease Intervention/treatment Phase
Gastric Cancer Pancreatic Cancer Biological: CT041 Phase 1

Detailed Description:

This is an open label, multi-center, Phase 1b clinical trial to evaluate the safety and efficacy of autologous claudin18.2 chimeric antigen receptor T-cell therapy in patients with advanced gastric or pancreatic adenocarcinoma.

Following consent, patients must have tumor tissue evaluated by CLDN18.2 IHC assay. Patients meeting all eligibility criteria will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of investigational drug product (CT041). Following manufacture of the drug product, subjects will receive preconditioning prior to CT041 infusion. All subjects will be asked to continue to undergo long-term gene safety follow-up.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 110 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: 3+3 dose escalation and expansion
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label, Multicenter, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
Actual Study Start Date : October 23, 2020
Estimated Primary Completion Date : June 1, 2025
Estimated Study Completion Date : September 1, 2035

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: anti-claudin18.2 chimeric antigen receptor T-cell therapy
Phase 1b will include two parts, dose escalation phase (Cohort A) followed by a dose expansion phase (Cohort B & C). Cohort C will evaluate the chosen dose in patients with advanced gastric cancer.
Biological: CT041
treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion

Primary Outcome Measures :
  1. Incidence of Treatment Related adverse events (AEs) [ Time Frame: day 1 - month 18 ]
    Incidence of Treatment Related AEs, AEs of special interest and serious adverse events (SAEs)

  2. Identification of Maximum Tolerated Dose (MTD) [ Time Frame: day 1 - month 18 ]
    Incidence of dose-limiting toxicities (DLTs)

  3. Objective Response Rate (ORR) [ Time Frame: day 1 - month 18 ]
    Rate of subjects in Cohort C experiencing >/= to PR per RECIST 1.1 as determined by IRC assessment

Secondary Outcome Measures :
  1. Time to Progression [ Time Frame: day 1 - month 18 ]
    Duration of time from CT041 treatment to progression of disease

  2. Duration of Response [ Time Frame: day 1 - month 18 ]
    Duration of time from first response to progression of disease

  3. Disease Control Rate [ Time Frame: day 1 - month 18 ]
    Percentage of patients response at least 90 days

  4. Progression free survival [ Time Frame: day 1 - month 18 ]
    duration time after CT041 treatment that patient lives without worsening of disease

  5. Overall survival [ Time Frame: day 1 - month 18 ]
    duration time after CT041 treatment that patient lives

  6. Objective Response Rate (ORR) [ Time Frame: day 1 - month 18 ]
    Rate of subjects in Cohort A & B experiencing >/= to PR per RECIST 1.1 as determined by the investigator

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 76 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients are eligible for screening for potential inclusion in the study:

  1. Voluntarily signed the ICF;
  2. Age ≥ 18 and < 76 years with pathologically/histologically confirmed diagnosis of adenocarcinoma of the stomach or gastroesophageal junction, referred to collectively as STAD, or pancreatic adenocarcinoma (PAAD);
  3. Must have CLDN18.2-positive tumor expression as determined by the CLDN18.2 IHC assay;
  4. Failed or been intolerant of prior lines of systemic therapy;
  5. Estimated life expectancy > 4 months;
  6. At least 1 measurable lesion per RECIST 1.1;
  7. ECOG performance status of 0 or 1;
  8. Sufficient venous access for leukapheresis collection and no other contraindications to leukapheresis;
  9. Patients should have reasonable CBC counts, renal and hepatic functions;
  10. Women of childbearing age must undergo a serum pregnancy test with negative results before screening and infusion and be willing to use effective and reliable method of contraception;
  11. Men must be willing to use effective and reliable method of contraception for at least 12 months after T-cell infusion;

Exclusion Criteria:

  1. Pregnant or lactating women;
  2. HIV, active hepatitis C virus (HCV), or active hepatitis B virus (HBV) infusion;
  3. Any uncontrolled active infection;
  4. AEs from previous treatment that have not recovered;
  5. Patients who have clinically significant thyroid dysfunction;
  6. Patients allergic to any drugs of the preconditioning regimen, tocilizumab, dimethyl sulfoxide (DMSO), or CT041 CAR-CLDN18.2 T-cell;
  7. Patients who have received prior cellular therapy such as (CAR T, TCR, tumor-infiltrating lymphocytes) or organ transplantation; Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression;
  8. Patients with heavy tumor burden such as significant lung disease
  9. Unstable/active ulcer or digestive tract bleeding or recent digestive surgery that may have increased risk of bleeding;
  10. Patients who have a history of esophageal or gastric resection with increased risk of bleeding or perforation;
  11. Patients requiring anticoagulant therapy such as warfarin or heparin;
  12. Patients requiring long-term antiplatelet therapy;
  13. Use of prednisone or other equivalent within 14 days before leukapheresis or preconditioning;
  14. Anticancer treatment within approximately 2 weeks prior to leukapheresis or approximately 3 weeks before preconditioning;
  15. Major surgery less than 1 week prior to leukapheresis or 3 weeks prior to preconditioning;
  16. Patients have clinical significant cardiac conditions that researchers believe that participating in this clinical trial may endanger the health of the patients;
  17. Patients have clinical significant pulmonary conditions;
  18. Patients known to have active autoimmune diseases;
  19. Patients with second malignancies in addition to STAD or PAAD;
  20. Patients have significant neurologic disorders;
  21. Patients are unable or unwilling to comply with the requirements of clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04404595

Layout table for location contacts
Contact: Hong Ma, MD 3462939392

Layout table for location information
United States, California
University of Southern California Recruiting
Los Angeles, California, United States, 90089
Contact: Heinz-Josef Lenz         
UCSD Recruiting
San Diego, California, United States, 92093
Contact: G Botta   
UCSF Not yet recruiting
San Francisco, California, United States, 94143
Contact: Julia Carnevale         
United States, Florida
Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: D Lakic   
United States, Illinois
University of Chicago Not yet recruiting
Chicago, Illinois, United States, 60637
Contact: Daniel Catenacci         
United States, Kansas
University of Kansas Cancer Center Not yet recruiting
Kansas City, Kansas, United States, 66160
Contact: Kasi Anup Kasi         
United States, Minnesota
Mayo Cancer Hospital Recruiting
Rochester, Minnesota, United States, 55905
Contact: A Schimek   
United States, New York
Memorial Sloan Kettering Cancer Center Not yet recruiting
New York, New York, United States, 10065
Contact: Geoffrey Ku         
United States, Ohio
Ohio State University Not yet recruiting
Columbus, Ohio, United States, 43210
Contact: Anne Noonan         
United States, Texas
TX Oncology-Baylor Charles Sammons Cancer Center Recruiting
Dallas, Texas, United States, 75246
Contact: A. Rodriguez   
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: M David   
Canada, Ontario
Princess Margaret Hospital Not yet recruiting
Toronto, Ontario, Canada, M5GH 2C1
Contact: Eric Chen         
Sponsors and Collaborators
CARsgen Therapeutics Co., Ltd.
Layout table for investigator information
Principal Investigator: Harry H Yoon, MD Mayo
Principal Investigator: Dae Won Kim, MD Moffitt
Layout table for additonal information
Responsible Party: CARsgen Therapeutics Co., Ltd. Identifier: NCT04404595    
Other Study ID Numbers: CT041-ST-02
First Posted: May 27, 2020    Key Record Dates
Last Update Posted: February 24, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CARsgen Therapeutics Co., Ltd.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases